tris pharma

Texas has reached a landmark $41.5 million settlement with Pfizer and Tris Pharma over the distribution of defective ADHD medication, Quillivant XR, which failed quality control from 2012 to 2018. The lawsuit accused the companies of manipulating drug tests to conceal manufacturing flaws that led to ineffective treatment for children on Medicaid. Families reported that the medication did not control ADHD symptoms, raising serious public health concerns. This case, initiated by a whistleblower, highlights the need for strong regulatory oversight in the pharmaceutical industry and accountability for corporate practices that endanger vulnerable populations. For more details, visit the full article.